170 results about "Inositol Phospholipids" patented technology

Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.

Formulations or delivery systems are provided for controlled release of therapeutically active agents. The delivery systems are composed of polymer and lipid materials and may be prepared as a gel, paste, solution, film, implant or barrier depending on the intended application. The polymer component of the matrix is the naturally occurring biomaterial, chitosan, or a mixture of chitin and chitosan. The lipid component may include phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidyl or a mixture thereof. The delivery system may be used for delivery of hydrophilic agents, hydrophobic agents or combinations thereof. The therapeutically active agents may be formulated within the matrix as free agents or incorporated into particles. In a preferred embodiment the agents are incorporated into polymeric particles that are dispersed throughout the matrix.

Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.

The first aspect of the invention relates to a bispecific antibody, which comprises a first functional domain for specific identification of phosphatidylinositol protein polysaccharide-3, a second domain for specific identification of human T cell antigen CD3, and a connection for connecting the functional domains. The second aspect of the invention relates to a nucleotide sequence encoding the above antibody. The third aspect of the invention relates to a carrier containing the above nucleotide sequence, and includes an expressive vector. The fourth aspect of the invention relates to a eukaryotic or prokaryotic expression system containing the above carrier. The fifth aspect of the invention relates to application of the above antibody to preparation of medicament for treating or preventing tumor.

Particles having a tap density less than about 0.4 g / cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.

The present invention relates to the discovery, identification and characterization of nucleotides that encode the G protein regulated phosphatidylinositol-3' kinase, a heterodimeric enzyme which produces the intracellular messenger phosphatidylinositol (3,4,5)-triphosphate in response to activation of trimeric G protein-linked receptors. This novel protein, comprised of a catalytic subunit, p120, and a regulatory subunit, p101, is found in cells of hematopoietic origin and is involved in immune system responses which cause inflammation. The presence of p101 subunit is largely responsible for the dramatic stimulation of kinase activity in the presence of activated trimeric G proteins. The invention encompasses p101 and p120 nucleotides; host cell expression systems, p101 and p120 proteins, fusion proteins, polypeptides and peptides, antibodies to these proteins, transgenic animals that express a p101 or p120 transgene, or recombinant knock-out cells and animals that do not express the p101 or p120 gene, antagonists and agonists of the enzyme, and other compounds that modulate p101 or p120 gene expression or enzyme activity that can be used for diagnosis, drug screening, clinical trial monitoring, and / or the treatment of inflammatory disorders.

The invention relates to the medical field of immunoassay, more specially, the invention provides a chemiluminescent immunoassay detection kit for phosphatidylinositol proteoglycan-3(GPC-3) and a preparation method thereof, and realizes the simultaneous serological detection of GPC-3 N terminal and C-terminal protein with the chemiluminescent immunoassay method. The kit has the advantages of simple sampling, convenient detection and accurate and specific technical method. The invention adopts a biotin-strapavidin system to coat antibodies and improve the efficiency of antibody coating and the linear range of detection as well as sensitivity, and can be conveniently used for the tracing observation of early diagnosis or treatment effect for primary carcinoma of liver.

A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and / or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

The present invention relates to a preparation suitable for the prevention and / or treatment of vascular disorders, comprising the following fractions:fraction a) consisting of long chain polyunsaturated fatty acids;fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine.fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

The invention discloses a pidotimod liposome solid preparation and a preparation method thereof. The pidotimod liposome with excellent quality is prepared by selecting pidotimod, phosphatidylinositol, cholesterol, stigmasterol and cremophor HEL 40 in specific weight ratios and then the pidotimod liposome is prepared into the solid preparation by a common preparation method. The liposome solid preparation and preparation method provided by the invention have the following beneficial effects: the liposome solid preparation has high encapsulation efficiency and uniform grain size; the retention time of medicaments in blood circulation is long; and the preparation method is simple and practical, is beneficial to improvement of the product quality and reduction of the toxic or side effect and is suitable for industrial large-scale production.

Provided are lipidic particles comprising phopatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and / or longer circulating time. These compositions can be used for therapeutic administration of the peptides, polypeptides and / or proteins.

A method of detecting a phosphatidylinositol-specific phospholipase C enzyme by means of a substrate which is cleaved by said enzyme and yields a dye when the chromophoric portion of the substrate is dimerized and oxidized; the invention teaches using in such method, as a novel substrate, a 3-indoxyl-myo-inositol-1-phosphate compound of formula (I) wherein R is selected from the group consisting of hydrogen and C1-4 alkyl, while R1, R2, R3, and R4 are radicals selected from the group consisting of hydrogen, halogen, cyano, nitro, carboxy, amino, alkyl-substituted amino and sulphonyl; or of a salt of said formula I compound. The invention provides for a safe and sensitive method of detection of potentially pathogenic bacterial activity of such microbes as Bacillus cereus, B. Thuringiensis, Staphy lococcus aureus and various Listeria strains in potentially infected materials including physiological samples or consumable goods such as foods and beverages.

Provided is a method for treatment of blood coagulation disorders. The method comprises administering to an individual compositions comprising lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. One or more peptides, polypeptides or proteins involved in the blood coagulation cascade are associated with the lipidic particles.

Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.

The present invention provides a method for modulating the replication of hepatitis C virus in a cell, comprising modulating the function of a phosphatidylinositol-4-kinase in the cell. In another aspect, the present invention provides a method for identifying a modulator of the replication of a hepatitis C virus, comprising: a) measuring the function of a phosphatidylinositol-4-kinase in the absence of a candidate compound; b) measuring the function of the phosphatidylinositol-4-kinase in the presence of the candidate compound; comparing the function measured in a) with the function measured in b), whereby a change in function in b) compared to the function in a) indicates that the candidate compound may a modulator of the replication of the hepatitis C virus. In a further aspect, the invention provides a method for the treatment of Hepatitis C viral infection by administering a virally effective amount of an inhibitor of PIK4CA.

Provided are lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and / or longer circulating time. These compositions can be used for therapeutic administration of the peptides, polypeptides and / or proteins.

The invention provides a liposome injection of a pharmaceutical composition of amoxicillin sodium and clavulanate potassium, which consists of amoxicillin sodium, clavulanate potassium, a liposome carrier, a lyoprotectant and a freely optional antioxidant, wherein the liposome carrier is egg yolk phosphatidylinositol and sodium taurocholate. The liposome injection has good preparation stability, liposome can avoid the fracture due to dehydration, fusion, ice crystal generation and the like during the freeze-drying process, and the liposome can still keep the good encapsulation rate after hydration and redissolution.

A modified phospholipase D having an ability to synthesize phosphatidylinositol which contains: (A) an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:2 by substitution of at least one of the amino acid residues at the 187-, 191- and 385-positions by other amino acid residue(s); or (B) an amino acid sequence of a polypeptide derived from the amino acid sequence as described in the above (A) by substitution, deletion, insertion and / or addition of at least one amino acid residue at a position different from the 187-, 191- and 385-positions and having an ability to synthesize phosphatidylinositol. By using this modified phospholipase D, phosphatidylinositol can be efficiently produced from a phospholipid. It is also intended to provide a method of screening a phospholipase D having an ability to synthesize an acylglycerophospholipid having glycol group.

The invention discloses an adsorbing material for industry wastewater with heavy metals and a preparation method of the adsorbing material. The adsorbing material is characterized by being prepared from the following components in parts by weight: 4 to 6 parts of cross-linked rectorite, 3 to 7 parts of kaolinite, 5 to 10 parts of graphene nano layer / MnO2 compound, 6 to 12 parts of chitosan-graphene composite material, 2 to 5 parts of polyacrylamide, 1 to 3 parts of aluminum sulfate, 1 to 2 parts of carboxymethyl chitosan, 1 to 2 parts of deacetylated chitin, 5 to 10 parts of ferric chloride, 5 to 10 parts of ammonium hydroxide, 1 to 2 parts of phosphatidylinositol, 2 to 4 parts of methylparaben, 0.2 to 0.6 part of sodium diacetate, 0.4 to 0.8 part of hydrogen peroxide, 0.1 to 0.6 part of peroxyacetic acid, 1 to 2 parts of sodium laurylsulfate, 80 to 100 parts of sodium hydroxide, 10 to 20 parts of ethylene glycol, 80 to 100 parts of ethanol, 0.1 to 0.2 part of sodium hydrosulfite, 70 to 100 parts of hydrochloric acid and 100 to 200 parts of deionized water.

Provided is an anti-fatigue agent or a physical endurance enhancer or a functional food having an anti-fatigue effect or a physical endurance-enhancing effect. Specifically provided are: a composition comprising phosphatidylinositol and coenzyme Q10; an anti-fatigue agent or a physical endurance enhancer comprising phosphatidylinositol and coenzyme Q10 as active ingredients; a functional food having an anti-fatigue effect or a physical endurance-enhancing effect, which comprises the compounds as active ingredients; use of phosphatidylinositol and coenzyme Q10 for the preparation of a composition having an anti-fatigue effect or a physical endurance-enhancing effect; and a method of enhancing an anti-fatigue effect or physical endurance, which includes ingesting a composition comprising those compounds as active ingredients.

The present invention relates to a combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor selected from the group consisting of a compound of formula (I) or a compound of formula (II), or pharmaceutically acceptable salt thereof, (b) a 17α-Hydroxylase / C17,20-lyase inhibitor (CYP17 inhibitor), specifically abiraterone acetate and 1-(2-Chloro-pyridin-4-yl)-3-(4-methyl-pyridin-3-yl)-imidazolidin-2-one or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for the treatment of a tumor disease; a pharmaceutical composition comprising such combination; use of such combination for the treatment of a tumor disease; a commercial package or product comprising such combination; and to a method of treating a patient having a tumor disease comprising administration of said combination to a patient in need thereof.

Provided is a taste improver that improves or decreases unpleasant bitterness, astringent taste, harsh taste, bitter taste, or the like that results from potassium salts, magnesium salts, calcium salts, and ammonium salts without adversely affecting savoriness of a food or drink. The taste improver includes a vegetable extract and / or a phospholipid. In the taste improver, the aforementioned vegetable extract includes a vegetable-derived glycoside and / or glycoside aglycone. In the taste improver, the aforementioned phospholipid is phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, and / or a lyso form thereof. Arginine is further added to the aforementioned taste improver. Trehalose and / or hydrogenated starch syrup are further added to the taste improver. A manufacturing method of such and an improvement method for the unpleasant bitterness, astringent taste, harsh taste, bitter taste, or the like caused by potassium salts, magnesium salts, calcium salts, and ammonium salts using these taste improvers. A food or drink including these taste improvers.

The invention provides an emulsion composition containing lecithin, DHA, other fat-soluble substances and purified water. The content of the purified water in the emulsion composition is more than 70% by weight, the weight ratio of the lecithin to the DHA is 1: (0.005-1), the particle size of fat balls in the emulsion is less than 5 mu m, and the other fat-soluble substances comprise one or more of the following components: arachidonic acid, linolenic acid, alpha-linolenic acid, gamma-linolenic acid, linoleic acid, conjugated linoleic acid, conjugated linoleic acid glyceride, phosphatidylserine, polyene phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl glycerol, phytosterol, plant sterol ester, plant stanol ester and medium and long-chain fatty acid. The invention further provides a preparation method of the emulsion composition and application of the emulsion composition in the functional aspects of supplementing phospholipids and unsaturated fatty acids by oral administration, protecting heart and brain blood vessels, reducing blood lipids, reducing blood pressure, treating fatty liver and the like.

The invention discloses a condensed heteroaryl derivative, and a preparation method and application thereof. The derivative disclosed by the invention is a phosphoinositide 3-kinase (PI3K) inhibitor which has the good inhabitation effect of the PI3K and the effect of inhibiting proliferation of cancer cells, so that the derivative can be used as a therapeutical agent for treating tumor.

The invention provides a method and a reagent kit for detecting phosphatidylinositol proteoglycan 3 with a fluorescence immunochromatographic method. The method for detecting phosphatidylinositol proteoglycan 3 with the fluorescence immunochromatographic method comprises the steps that the fluorescence characteristic of rare earth fluorescent microspheres is utilized and combined with a mature immunochromatography technology, and fluorescent quantitative determination of phosphatidylinositol proteoglycan 3 is achieved by optimizing all steps. The reagent kit is characterized by being composed of a test paper card and an immunofluorescence chromatography analysis meter. A preparing method of the reagent kit comprises the steps of preparation of a specificity high-appetency monoclonal antibody, antibody labeling with rare earth fluorescent microspheres, preparation of a fluorescent microsphere combined pad and a nitrocellulose membrane sprayed with the antibody, assembling and wrapping of test paper strips, and the like. In the detection process, a sample is operated as a specification, a result is subjected to quantitative determination with the immunofluorescence chromatography analysis meter, and the advantages of being easy, convenient and fast to implement, suitable for field detection and the like are achieved.

The invention discloses a glypican-3 quantitative analysis kit. The glypican-3 quantitative analysis kit comprises a GPC3 standard product, an acridinium ester-marked glypican-3 antibody solution, and a nano-magnetic microsphere solution which is coupled with glypican-3 antibodies. The invention further provides a preparation method for the kit. The GPC3 nano-magnetic microsphere chemiluminescence immunoassay determination kit which takes acridinium ester as a luminescence marker provided by the invention has the characteristics of high sensitivity, wide linear range, high specificity, stable marker, low cost and the like; the detecting process of the kit is simple and quick; the glypican-3 can be detected by only requiring a micro sample.